Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26746550 | 1.00 | APEX1 (0.41) | APEX1BLMKMT2AMEN1CYP2C19 | |
| SCHEMBL24796275 | 0.88 | APEX1 (0.42) | APEX1BLMKMT2AMEN1CYP2C19 | |
| SCHEMBL21384008 | 0.88 | APEX1 (0.42) | APEX1BLMKMT2AMEN1CYP2C19 | |
| SCHEMBL24796375 | 0.88 | APEX1 (0.42) | APEX1BLMKMT2AMEN1CYP2C19 | |
| SCHEMBL26747453 | 0.88 | KMT2A (0.41) | APEX1BLMKMT2ACYP3A4CYP2D6 | |
| SCHEMBL26747459 | 0.88 | KMT2A (0.41) | APEX1BLMKMT2ACYP3A4CYP2D6 | |
| SCHEMBL26746513 | 0.87 | KMT2A (0.37) | KMT2AMEN1CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL26746659 | 0.84 | PER2 (0.35) | KMT2AMEN1CYP2C19CYP3A4TP53 | |
| SCHEMBL26746661 | 0.84 | PER2 (0.35) | KMT2AMEN1CYP2C19CYP3A4TP53 | |
| SCHEMBL24796415 | 0.83 | HPGD (0.43) | APEX1BLMKMT2AMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | APEX1 2901/4885BLM 4161/4885KMT2A 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.